Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort studyBrandon Webb, Samuel M. Brown, Ithan D. Peltan et al.|The Lancet Rheumatology|2020Cited by 309
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)Iván O. Rosas, Min Bao, Andrew Ustianowski et al.|EClinicalMedicine|2022Cited by 37
Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)Jennifer L. Crombie, Marcelo C. Pasquini, Loretta J. Nastoupil et al.|Blood|2023Cited by 17
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistryMaría Silvina Odstrcil Bobillo, Matthew J. Frigault, Swetha Kambhampati et al.|Blood|2024Cited by 7
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistrySairah Ahmed, Jennifer L. Crombie, Avyakta Kallam et al.|Blood|2024Cited by 6